Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
95,714,968
-
Total 13F shares
-
27,534,073
-
Share change
-
+117,830
-
Total reported value
-
$1,131,426,201
-
Put/Call ratio
-
86%
-
Price per share
-
$40.99
-
Number of holders
-
176
-
Value change
-
-$8,297,966
-
Number of buys
-
78
-
Number of sells
-
78
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2019
As of 30 Sep 2019,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
176 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,534,073 shares.
The largest 10 holders included
Versant Venture Management, LLC, ARK Investment Management LLC, Nikko Asset Management Americas, Inc., NEA Management Company, LLC, Cormorant Asset Management, LP, WADDELL & REED FINANCIAL INC, WELLINGTON MANAGEMENT GROUP LLP, FEDERATED INVESTORS INC /PA/, Bellevue Group AG, and CREDIT SUISSE AG/.
This page lists
176
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.